Logo

Lupin Entered into a Distribution and Marketing Agreement with Biomm for Pegfilgrastim Biosimilar in Brazil

Share this

Lupin Entered into a Distribution and Marketing Agreement with Biomm for Pegfilgrastim Biosimilar in Brazil

Shots:

 

  • Under the terms of the agreement, Biomm will be responsible to distribute and market biosimilar Pegfilgrastim in Brazil
  • The US FDA has accepted the BLA for a proposed biosimilar to reference Neulasta (pegfilgrastim) through a filing using the 351(k) pathway
  • Pegfilgrastim is designed to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with CT. The company has developed and commercialized branded and generic formulations, biotechnology products, and APIs in ~ 100 markets in the US, India, South Africa, APAC, LATAM, EU, and the Middle East regions

Ref: Lupin | Image: Lupin 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions